1 / 28

Swedish - American Life Science Summit Stockholm August 20, 2009 Magnus Nilsson, CEO

Swedish - American Life Science Summit Stockholm August 20, 2009 Magnus Nilsson, CEO. Agenda. Company background Market presence and growth Product/therapy areas Outlook 2009. 2. Vitrolife – a global life science company.

hester
Download Presentation

Swedish - American Life Science Summit Stockholm August 20, 2009 Magnus Nilsson, CEO

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Swedish - American Life Science Summit Stockholm August 20, 2009 Magnus Nilsson, CEO

  2. Agenda Company background Market presence and growth Product/therapy areas Outlook 2009 2

  3. Vitrolife – a global life science company • A global life science company (Bio-Med Tech). Main sites in Gothenburg and Denver, Colorado • Developing, manufacturing and selling nutrient solutions (media) and instruments for fertility treatments and lung transplantations. • Growing and profitable business founded in 1994. • Approx 160 employees. • Sales in more than 85 countries. Local presence Nordic countries, US, Canada, Italy, Benelux, Austria, Germany, China, Japan, Australia, France • Listed on the OMX Nordic Exchange’s Nordic Small Cap list since 2001. Company Background

  4. Our Vision Vitrolife strives to be the leading supplier of media and other advanced disposables, used by hospitals and laboratories performing fertility treatment and other therapies where cells or tissues are used or are a part of the therapy. 4 Company Background

  5. Vitrolife – Strategy 5 Company Background

  6. A Process organisation to reflect the value chain Order to Delivery Product Life Cycle Management Purchasing Production QC Sales Order Distribution Product idea valuation Product development Marketing Supporting Processes Quality Assurance Finance/Information IT Human Resources Administration 6 Company Background

  7. Vitrolife – Reaching the global market New offices in China and Japan 2009 7 Market presence and growth

  8. Sales by region rolling 12 months 8 Market presence and growth

  9. Sales and growth rate 2009 9 Market presence and growth

  10. Sales and growth rate 2009 - Fertility Share of sales of Vitrolife Growth rate for Vitrolife Growth rate for Vitrolife Regional share of global cycles ~ 1.0 million cycles performed world wide per year 10 Market presence and growth

  11. Highlights of 2009 • Sales first half year +23% • Increased investment in R&D and marketing • Fertility: Strong development in Asia, Europe and Middle East • Transplantation: Positive progress for the clinical study in Canada for STEEN Solution™ • Successfull start up of the new offices in Asia • Dividend 0.40 SEK/share paid out • EBITDA 28,4% of sales • Operating margin 14,4% 24 quarters of continuous operating profits 26 quarters in a row with better sales than previous year Market presence and growth

  12. Key Financials: Investing in growth for the future SEKm 14% of Sales invested in R&D activities Investing in growth 12 Market presence and growth

  13. STEM CELL CULTIVATION Product areas - a genius combination TRANSPLANTATION FERTILITY • Customers/markets: • Public clinics • ~ 200 Lung transpl clinics / ~ 2000 all transplantations • Subsidized • ~3000 Lungs/ ~ 50000 all transplantations • Customers/markets: • Private and public clinics/ specialized laboratories • ~ 3000 clinics • Partly subsidized • ~ 1 million clin. IVF treatm. • Customers/markets: • Public specialized laboratories /research institutions and private companies • ~ 400 institutions / 150 companies • Subsidized & private • Research, in clinics 2-5 years 13 Product /Therapy areas

  14. New unique needle for the collection of human oocytes, Swemed Sense™, recently launched and approved for sales in Europe Potential market estimated to EUR 50 million Fertility – Competitive advantage FERTILITY • A complete range of advanced clinical products • Regulatory approval • CE mark • FDA 510(k) • State of the art production facilities • Industry leading QC • Global market reach • External collaboration with the leading scientist 14 Product /Therapy areas

  15. History of Innovations FERTILITY Beyond HSA –Recombinant media r-S1™/ r-S2™ First sequential media G1™/ G2™ v. 2 New technique -follicle aspiration needle with ultrasound probe Pharmaceutical-grade media IVF™-50 Closer to NatureGIII Series™ v.3 ICSI Medium 1983 1994 1995 1998 2001 2002 Breakthrough Innovations Unique aspiration needle – SWEMED ™ Sense Acquisition of SWEMED lab EmbryoGlue®Implantation promoting medium GIII Series ™CE marked Ultrarapid vitrification 15 2004 2005 2006 2007 2008 2003 Product /Therapy areas

  16. Product portfolio development Strategy: Portfolio expansion through R&D and acquisitions to optimize market synergies: FERTILITY Target: Increase product offering value per cycle with 50% 16 Product /Therapy areas

  17. STEM CELL CULTIVATION Stem Cell cultivation • Products for human embryo stem cells and cryo preservation of stem cells • State of the art production facilities • Industry leading QC • Cooperation with leading scientist In VitroHes researchers can successfully grow human stem cells and maintain pluri potency 17 Product /Therapy areas

  18. Giant market expectations in cell therapy STEM CELL CULTIVATION Source: Jain Pharmatech 18 Product /Therapy areas

  19. Cell Therapy – Situation analysis STEM CELL CULTIVATION • Clinical applications for MSC, HSC, CBSC, FNSC • >3 years before therapies based on hESC reach clinic due to: • Difficulties to control differentiation • Scaling up production • Ethically controversial • Regulatory authorities 19 Product /Therapy areas

  20. Stem cell culture media – Regulatory STEM CELL CULTIVATION • Harmonisation of regulatory requirements and a long term view is a need for a safe treatment • US • Regulated by FDA/ CBER • Classified as Class 1 Medical Device, exempted from 510(k) • EU • Classified as non Medical Device • To be produced according to GMP 20 Product /Therapy areas

  21. STEM CELL CULTIVATION Stem Cell Cultivation – Focus areas • Increase focus on development of new ”clinical grade” stem cell media together with our partners. • Fulfill the clinical requirements as set out in other areas Product /Therapy areas

  22. Transplantation – the new way TRANSPLANTATION The new method radically increases the availability of organs for transplantation • Pioneering lung perfusion system (ex vivo and at 37ºC) • Clinical trial in North America of Steen Solution™ • Innovative equipment for organ evaluation ex vivo • Development of perfusion systems for other organs • Preclinical trials with other organs e.g. liver, heart 22 Product /Therapy areas

  23. STEEN Solution™ - Focus Area TRANSPLANTATION • Finish clinical studies in North America and apply for marketing authorization for Steen Solution™ in the U.S. Clinical results so far very promising. • 25 lungtransplantations performed in clinic so far • Continue launch of STEEN Solution™ in Europe by training and education in the STEEN Solution™ method to get market acceptance • Developing of and clinical trials with additional products needed for a lung-assessment with Steen Solution ™. Product /Therapy areas

  24. Vitrolife – STEEN SolutionTM TRANSPLANTATION Problem STEEN Solution™ Advantage • More organs can be used • More organs available for transplantation • More organs can be used in time (lower cost) • Fewer deaths caused by lack of organs • Functional testing • Large number of potential donors (including donation after cardiac death) • Maximum time >24 hours outside the body • More patients can be provided with new lungs • >70% of donated organs are not used • Too few organs to transplant • Short of time, a maximum of 8-12 hours outside the body • Patients die while waiting for organs         Product /Therapy areas

  25. Vitrolife – STEEN SolutionTM TRANSPLANTATION Before STEEN Sol. Costs for products per evaluation (SEK) ca 10.000 > 30.000 Potential number of transplantations ca 3.000 > 20.000 Market potential*, lungs only (SEK million) ca 35 > 600 * Including research market Approved in Europe 2006, and in Australia 2008. The method is also being developed for other organs, e.g. liver. Product /Therapy areas

  26. Outlook 2009 • Continued execution of main strategy: • Establish direct sales on all major markets covering 80% of all treatments • Exploit market synergies with broader product portfolio through development and/or acquisitions • Increase gross margin through continuous improvement of operations • One major new product launch in Product Area Fertility • Support launch of STEEN Solution™ in Europe and prepare for market introduction in USA and Canada • Strong R&D focus with gradually increasing efforts in Transplantation and Stem Cell Cultivation • Maintain profitable growth and operational strong cash flow Outlook 2009

  27. With sustainable profit & cash flow… …reaching the global market …investing in growth …for the future

More Related